Education
About Us
Working with TipRanks
Follow Us
Ardelyx (ARDX)
NASDAQ:ARDX
ARDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.02 - $9.33
Previous CloseN/A
Volume1.36M
Average Volume (3M)4.91M
Market Cap
$1.15B
Enterprise Value$1.14B
Total Cash (Recent Filing)$34.44M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.99
Next Earnings
May 01, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding238,356,220
10 Day Avg. Volume5,503,860
30 Day Avg. Volume4,911,918
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.67
Price to Cash Flow (P/CF)31.20
P/FCF Ratio31.20
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.03
Enterprise Value/Ebitda-68.25
Forecast
1Y Price Target
$11.31Price Target Upside133.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Financial Performance4Q24 was ARDX's first product-driven profitable quarter, and minimal cash impact from operations is expected through FY25.
Market OpportunitiesIbsrela and Xphozah continue to build momentum in large market opportunities with no second-line competition, supporting a clear path to returned profitability.
Bears Say
Investor SentimentA significant overhang on investor sentiment and the stock is expected until there is a resolution to the uncertainty around Medicare patient access for XPHOZAH.
Medicare CoverageXPHOZAH's near-term and long-term outlook remains uncertain since it became unavailable under Medicare Part D.
Stock RatingAnalysts anticipate a substantial drop in XPHOZAH sales due to its inclusion in the Medicare bundle, leading to a downgrade of the stock rating.
---
Ownership Overview
3.18% Insiders
19.39% Mutual Funds
0.43% Other Institutional Investors
64.22% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARDX FAQ
What was Ardelyx’s price range in the past 12 months?
Ardelyx lowest stock price was $4.02 and its highest was $9.33 in the past 12 months.
What is Ardelyx’s market cap?
Ardelyx’s market cap is $1.15B.
When is Ardelyx’s upcoming earnings report date?
Ardelyx’s upcoming earnings report date is May 01, 2025 which is in 6 days.
How were Ardelyx’s earnings last quarter?
Ardelyx released its earnings results on Feb 20, 2025. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of $0.004 by $0.016.
Is Ardelyx overvalued?
According to Wall Street analysts Ardelyx’s price is currently Undervalued.
Does Ardelyx pay dividends?
Ardelyx does not currently pay dividends.
What is Ardelyx’s EPS estimate?
Ardelyx’s EPS estimate is -0.11.
How many shares outstanding does Ardelyx have?
Ardelyx has 238,356,220 shares outstanding.
What happened to Ardelyx’s price movement after its last earnings report?
Ardelyx reported an EPS of $0.02 in its last earnings report, beating expectations of $0.004. Following the earnings report the stock price went down -10.063%.
Which hedge fund is a major shareholder of Ardelyx?
Currently, no hedge funds are holding shares in ARDX
---
Ardelyx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.31 (133.20% Upside)
$11.31 (133.20% Upside)
Blogger Sentiment
Bullish
ARDX Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 574.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $388.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.11%
12-Months-Change
Fundamentals
Return on Equity
-23.01%
Trailing 12-Months
Asset Growth
46.43%
Trailing 12-Months
Company Description
Ardelyx
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
---
ARDX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Ardelyx demonstrated strong financial growth and successful product launches, particularly with IBSRELA and XPHOZAH, which led to significant revenue increases and a positive financial position. However, challenges such as the loss of Medicare Part D coverage for XPHOZAH and increased operational expenses present potential hurdles. Overall, the positive achievements appear to outweigh the lowlights.Read More>---
ARDX Stock 12 Month Forecast
Average Price Target
$11.31
▲(133.20% Upside)
Technical Analysis
Celldex
―
MiMedx Group
―
Ocular Therapeutix
―
Aurinia Pharmaceuticals
―
Liquidia Technologies
―
Best Analysts Covering ARDX
1 Year
1 Year Success Rate
7/15 ratings generated profit
1 Year Average Return
+62.52%
reiterated a buy rating 6 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of +62.52% per trade.
---